Skip to content

Study for comparison of Efficacy and safetystudy between rivaroxaban and warfarin in prophylactic anticoagulant therapy for nephrotic syndrome

Efficacy and safety comparision between rivaroxaban and warfarin in prophylactic anticoagulant therapy for nephrotic syndrome

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000036449
Enrollment
Unknown
Registered
2020-08-23
Start date
2021-01-01
Completion date
Unknown
Last updated
2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

nephrotic syndrome

Interventions

2:Rivaroxaban

Sponsors

Shanghai First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1) Aged 18 to 80 years old male and female; 2) Clinical diagnosis of nephrotic syndrome, and the serum albumin was < 25g / dl at admission; 3) The patients should receive routine VTE prophylactic treatment after the diagnosis was confirmed.

Exclusion criteria

Exclusion criteria: 1) Patients receiving anticoagulant therapy due to catheter-related thrombosis; 2) VTE, varicose vein, phlebitis and other vascular diseases existed in the past; 3) The clinical manifestations of DVT / PE were not confirmed by imaging examination; 4) Previous blood related diseases or severe coagulation disorders; 5) Severe hepatic and renal insufficiency; 6) Oral anticoagulants were used before enrollment; 7) There were contraindications of heparin use / anticoagulation, heparin allergy / hit, or failed to use routine heparin anticoagulation due to other factors; 8) Combined with heart failure, respiratory failure and refractory hypertension; 9) Pregnancy / lactation.

Design outcomes

Primary

MeasureTime frame
vte;bleeding;death;

Countries

China

Contacts

Public ContactChen Qiong

Shanghai First People's Hospital

smilecq_0@126.com+86 13651792141

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026